Global Leading Market Research Publisher QYResearch announces the release of its latest report “Sterile Defibrinated Horse Blood – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Sterile Defibrinated Horse Blood market, including market size, share, demand, industry development status, and forecasts for the next few years.
For clinical microbiology laboratories, pharmaceutical quality control (QC) labs, and biomedical research institutions, cultivating fastidious microorganisms (bacteria with complex nutritional requirements) requires specialized growth media. Standard culture media lack the growth factors, hemin (X factor), and nicotinamide adenine dinucleotide (V factor) needed for pathogens like Haemophilus influenzae, Neisseria species, and Streptococcus pneumoniae. The sterile defibrinated horse blood addresses this through enriched culture media supplementation: mechanically defibrinated (fibrin clot removed), sterile horse blood added to base media (chocolate agar, blood agar) to provide essential nutrients for demanding pathogen isolation and identification. According to QYResearch’s updated model, the global market for Sterile Defibrinated Horse Blood was estimated to be worth US$ 89.91 million in 2025 and is projected to reach US$ 143 million, growing at a CAGR of 6.9% from 2026 to 2032. In 2024, the global production of Sterile Defibrinated Horse Blood reached 672.02 kiloliters, with an average selling price of US$ 135.16 per liter. Sterile Defibrinated Horse Blood is a high-quality, sterile blood product designed for microbiology laboratories. It is essential for preparing enrichment media, particularly for the cultivation of a wide range of demanding microorganisms. Mechanically defibrated, this blood remains free of fibrin clots, providing consistent performance in microbiology diagnostics and research.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097337/sterile-defibrinated-horse-blood
1. Technical Architecture: Defibrination Process and Quality Specifications
Sterile defibrinated horse blood is characterized by its processing method and quality parameters, ensuring consistent performance in microbiological applications:
| Specification | Typical Value | Critical Quality Attribute |
|---|---|---|
| Sterility | No bacterial/fungal growth (USP <71>) | Prevents culture contamination |
| Defibrination method | Mechanical agitation (glass beads) | Removes fibrin clots (clotting interferes with media preparation) |
| Hemoglobin content | 12-15 g/dL | Indicator of red blood cell integrity |
| pH | 7.0-7.4 | Optimal for bacterial growth |
| Endotoxin level | <10 EU/mL | Low endotoxin prevents inhibition of sensitive organisms |
| Color | Bright red (oxygenated) | Indicates freshness and proper handling |
Key technical challenge – maintaining sterility and consistency across batches: Horse blood collection, defibrination, and aseptic filling must prevent contamination. Over the past six months, several advancements have emerged:
- Thermo Fisher Scientific (February 2026) introduced a “single-donor” sterile defibrinated horse blood product with full traceability (veterinary health certificates, donor screening), reducing batch-to-batch variability by 50% compared to pooled collections.
- BioMérieux (March 2026) commercialized a ready-to-use chocolate agar plate with defibrinated horse blood and added growth factors (IsoVitaleX), eliminating QC labs’ need to prepare plates in-house, reducing labor by 80%.
- TCS Biosciences (January 2026) launched a “low-endotoxin” defibrinated horse blood (≤1 EU/mL) for pharmaceutical QC applications (sterility testing, endotoxin-sensitive assays), meeting USP and EP requirements.
Industry insight – horse blood vs. alternatives for microbiology media:
| Blood Source | Advantages | Disadvantages | Typical Applications |
|---|---|---|---|
| Horse blood | Rich in growth factors, consistent quality, low hemolysis | Higher cost | Chocolate agar (Haemophilus, Neisseria), blood agar (streptococci) |
| Sheep blood | Lower cost, widely available | Lower nutrient content | Routine blood agar |
| Rabbit blood | High sensitivity for hemolysis detection | Expensive, limited supply | Hemolysis typing |
| Synthetic alternatives | No animal welfare concerns, consistent | Higher cost, unproven for all organisms | Research applications |
2. Market Segmentation: Specification and Application
The Sterile Defibrinated Horse Blood market is segmented as below:
Key Players: Thermo Fisher Scientific (US), TCS Biosciences (UK), BioMérieux (France), E & O Laboratories (UK), Southern Biological (Australia), Biowest (BioNordic A/S, France), Pel-Freez Biologicals (US), Trafalgar Scientific (UK), HemoStat Laboratories (US), EWC Diagnostics (India), Dutscher (France), Serana Europe (Germany), Kraeber & Co. GmbH (Germany), Bio Nutrientes Do Brasil (Brazil), Lampire Biological Laboratories (US), Innovative Research Inc. (US), Colorado Serum (US), SSI Diagnostica (Denmark), SR Group (India), Szabo-Scandic (Austria), Rockland Immunochemicals (US), LABone Scientific (China), Quad Five (Materials Bio Inc., US), Guangzhou Ruite Biotechnology (China), Obio Technology (Shanghai, China), Beijing Solarbio Science & Technology (China), Nanjing SenBeiJia Biological Technology (China)
Segment by Specification (Volume):
- 50ml – Largest volume segment (30% of 2025 units). Small labs, research, occasional use.
- 100ml – 25% of units. Mid-volume labs.
- 250ml – 20% of units. High-volume clinical labs.
- 500ml – 15% of units. Reference labs, media preparation facilities.
- Other (1L, custom) – 10% of units. Industrial media manufacturers.
Segment by Application:
- Biomedicine Research – Dominant segment (95%+ of revenue). Clinical diagnostics (hospital microbiology labs), pharmaceutical QC (sterility testing, environmental monitoring), veterinary diagnostics, food safety testing.
- Other – Vaccine production, research (5% of revenue).
Typical user case – clinical microbiology lab: A hospital microbiology lab processes 500 patient samples daily (sputum, blood, urine, wound swabs). Chocolate agar plates (Haemophilus influenzae, Neisseria gonorrhoeae) and blood agar plates (streptococci, staphylococci) are prepared using sterile defibrinated horse blood (5-10% v/v). Annual consumption: 20L horse blood (200 × 100ml bottles). Cost: $2,700 ($135/L). Value: enables accurate identification of respiratory pathogens, bloodstream infections, and sexually transmitted infections. Reimbursement for culture-based ID: $50-200 per positive culture → lab revenue $500k-2M annually → blood cost negligible.
Exclusive observation – “ready-to-use” media trend: Pre-poured chocolate agar and blood agar plates with defibrinated horse blood are growing at 8% CAGR (vs. 6.9% for bulk blood). Ready-to-use plates eliminate in-house media preparation (labor, autoclaving, quality control), reducing contamination risk and saving 30-60 minutes of technician time daily. Premium pricing: $2-5 per plate vs. $0.50-1.00 for bulk blood + base media.
3. Regional Dynamics and Diagnostic Testing Growth
| Region | Market Share (2025) | Key Drivers |
|---|---|---|
| North America | 35% | Largest clinical diagnostics market (US), Thermo Fisher/Pel-Freez/Lampire/Rockland/Colorado Serum/Innovative Research/Quad Five leadership |
| Europe | 30% | Strong microbiology infrastructure (UK, Germany, France, Denmark), TCS/BioMérieux/E&O/Biowest/Dutscher/Serana/Kraeber/SSI leadership |
| Asia-Pacific | 25% | Fastest-growing (8% CAGR), China (Guangzhou Ruite, Obio, Solarbio, SenBeiJia), India (EWC, SR Group), Japan |
| RoW | 10% | Emerging diagnostics (Brazil – Bio Nutrientes, Australia – Southern Biological) |
Exclusive observation – “antimicrobial resistance” (AMR) as growth driver: Global AMR crisis (5M deaths annually attributed to resistant infections) drives demand for accurate culture-based susceptibility testing (AST). Horse blood-enriched media is essential for fastidious organisms (S. pneumoniae, H. influenzae) in AST. WHO’s Global Action Plan on AMR (updated 2025) emphasizes strengthening laboratory capacity, increasing testing volumes, and driving demand for culture media supplies.
4. Competitive Landscape and Outlook
| Tier | Supplier | Key Strengths | Focus |
|---|---|---|---|
| 1 | Global diagnostics leaders | Thermo Fisher (US), BioMérieux (France), SSI Diagnostica (Denmark) | Integrated media + blood products, global distribution, premium pricing (+20-30%) |
| 2 | Regional blood specialists | TCS (UK), E&O (UK), Biowest (France), Pel-Freez (US), Lampire (US), Colorado Serum (US), Rockland (US), Southern Biological (Australia), Serana (Germany), Kraeber (Germany), Bio Nutrientes (Brazil) | Regional distribution, quality assurance, competitive pricing |
| 2 | Asian suppliers | Guangzhou Ruite, Obio, Solarbio, SenBeiJia (China), EWC, SR Group (India) | Cost leadership (30-50% below Western), domestic market, export |
Technology roadmap (2027-2030):
- Animal-free synthetic blood substitutes – Chemically defined growth factors replacing horse blood for selected applications (e.g., Neisseria, Haemophilus). Pilot stage (Thermo Fisher, BioMérieux).
- Longer shelf-life defibrinated blood – Extended stability from 24 months to 36 months with optimized anticoagulants and storage conditions.
- Smaller unit sizes for point-of-care – 10ml and 20ml vials for rapid diagnostic tests (RDTs) and near-patient testing (decentralized microbiology).
With 6.9% CAGR and 672 kiloliters produced in 2024, the sterile defibrinated horse blood market benefits from clinical microbiology testing growth, AMR surveillance, and pharmaceutical QC requirements. Key growth drivers: infectious disease prevalence, hospital-acquired infection (HAI) monitoring, and vaccine development (growth factor requirements). Risks include animal welfare concerns (horse blood collection), competition from synthetic alternatives, and regulatory changes (animal product import restrictions).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
